Clinical trials: open to volunteers, sponsored by Zhejiang Cancer Hospital
Breast Cancer
Pucotenlimab and Anlotinib in Combination With Chemotherapy
A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer.
- Trial name
- NCT07896668
- Testing
- LP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Thrombocytopenia, Cancer Treatment-induced Thrombocytopenia
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients.
- Trial name
- NCT07441720
- Testing
- umbilical cord blood
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC)
Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric…
- Conditions
- Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC), Ascites, Malignant
- Trial name
- NCT07855640
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Cancinoma (NPC)
Platinum-Free Regimen in Nasopharyngeal Carcinoma
This study aimed to investigate the efficacy of a platinum-free neoadjuvant regimen (gemcitabine, camrelizumab, endostar, and low-dose radiotherapy) followed by a risk-adapted therapeutic strategy in patients with locally…
- Trial name
- NCT07794488
- Testing
- Endostar (recombinant human endostatin injection)
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Peritoneal Metastasis (GCPM)
A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
This study is a prospective, single-center, open-label, exploratory phase II clinical trial aimed at evaluating the safety, tolerability, and preliminary efficacy of low-dose radiotherapy (LDR) sequentially combined with…
- Trial name
- NCT07784413
- Testing
- low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Breast Cancer, HER2-negative Breast Cancer
Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-tumor activity of metronomic oral paclitaxel solution in patients with advanced HER2-negative breast cancer who have previously…
- Trial name
- NCT07602907
- Testing
- Paclitaxel Oral Solution (50mg/qd), Paclitaxel Oral Solution (100mg/TIW), Paclitaxel Oral Solution (OTD)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer, Radiation
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Primary Objectives： Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR/MSS mid - low rectal cancer.
- Conditions
- Rectal Cancer, Radiation, AK112
- Trial name
- STAR (NCT07162714)
- Testing
- radiotherapy, Ivonescimab (20mg/kg Q3W), Non-operative Management
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Uterine Cervical Neoplasms
Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
- Trial name
- NCT07702838
- Testing
- Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Pancreatic Cancer
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
This is a Phase Ib/II study to evaluate the safety, tolerability and efficacy of IBI343 in combination with chemotherapy in patients with advanced pancreatic cancer, including a Phase Ib safety introduction and Phase II expansion…
- Trial name
- NCT07692750
- Testing
- IBI343+ capecitabine, IBI343+Capecitabine+oxaliplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
This study aims to develop an AI-based predictive tool to help clinicians more accurately determine whether breast cancer patients can benefit from HER-2-targeted antibody-drug conjugate (T-DXd) therapy before treatment.
- Trial name
- NCT07689929
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Zhejiang Cancer Hospital
Cervical Cancer, Recurrent Cervical Cancer
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis…
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Trial name
- NCT07673211
- Testing
- Biospecimen collection (peripheral blood and paraffin tumor tissue)
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Hematological Malignancies B
Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
The goal of this clinical trial is to evaluate the biodistribution, radiation dosimetry, safety, and time-dependent image quality of ^68^Ga-EV203 injection in patients with hematological malignancies (multiple myeloma…
- Trial name
- NCT07670949
- Testing
- 68Ga-EV203 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer (OvCa)
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in…
- Trial name
- RESO (NCT07586449)
- Testing
- Senaparib capsules(20mg)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
High-risk R/R LBCL
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk…
- Trial name
- CAR-T+ASCT (NCT07538635)
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
MALT Lymphoma
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
This is a prospective, multicenter Phase 2 clinical trial named the MALT-RO study, evaluating ultra-low-dose radiation therapy followed by orelabrutinib as first-line treatment for adults with Stage I-II MALT lymphoma.
- Trial name
- NCT07554898
- Testing
- Orelabrutinib, Ultra-low-dose Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
Evaluate the initial dose-effect and time-effect relationship of the injection product NC527-X
- Trial name
- NCT07538648
- Testing
- Experimental:Preoperative injection of NC527-X
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
This study adopts a multicenter, natural selection, observational design, and plans to enroll patients with HER-2 positive advanced or metastatic breast cancer treated at approximately 20 research centers nationwide.
- Trial name
- NCT07455188
- Testing
- Antitumor treatment plan
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Zhejiang Cancer Hospital
Pirtobrutinib, Sintilimab
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
This is a prospective, single-Arm, phase II clinical study evaluating the efficacy and safety of thiotepa in combination with pirtobrutinib (a BTK Inhibitor) and sintilimab (a PD-1 Inhibitor) for frail or relapsed/refractory…
- Conditions
- Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
- Trial name
- NCT07416890
- Testing
- Thiotepa, Pirtobrutinib , Sintilimab(TPS)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang Cancer Hospital